^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HS627 (pertuzumab biosimilar)

    i
    Associations
    News

    Trials

    Company:
    Zhejiang Hisun
    Drug class:
    HER2 dimerization inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer (NRG-BR004) (NCT03199885)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    09/26/2024
    Initiation :
    04/05/2019
    Primary completion :
    04/30/2024
    Completion :
    05/15/2025
    ER • PGR • IL2
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • Tecentriq (atezolizumab) • paclitaxel • docetaxel • Perjeta (pertuzumab) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • TQB2440 (pertuzumab biosimilar) • BCD-178 (pertuzumab biosimilar) • EG1206A (pertuzumab biosimilar) • GB221 (coprelotamab) • HS627 (pertuzumab biosimilar) • SIBP-01 (trastuzumab biosimilar)
    Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer (NCT02003209)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/21/2024
    Initiation :
    01/15/2014
    Primary completion :
    10/31/2016
    Completion :
    12/31/2024
    HER-2 • ER
    |
    TILs
    |
    Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • goserelin acetate • Herwenda (trastuzumab biosimilar) • TQB2440 (pertuzumab biosimilar) • BCD-178 (pertuzumab biosimilar) • EG1206A (pertuzumab biosimilar) • GB221 (coprelotamab) • HS627 (pertuzumab biosimilar) • SIBP-01 (trastuzumab biosimilar)
    Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel (NCT04514419)
    Phase 3
    Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd
    Recruiting
    Last update posted :
    08/17/2020
    Initiation :
    06/30/2020
    Primary completion :
    11/20/2021
    Completion :
    11/20/2021
    HER-2 • ER • PGR
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • HS627 (pertuzumab biosimilar)